You need to enable JavaScript to run this app.
Recon: FDA approves Sunovion Parkinson’s drug; Oxford-AZ vaccine moving to Phase 2/3 trials
Recon
Michael Mezher
ReconMichael Mezher
ReconMichael Mezher